Long-term Study for People Previously Treated with Ciltacabtagene Autoleucel

Program Overview

The study is designed to collect information on any delayed side effects that may occur after receiving ciltacabtagene autoleucel (cilta-cel), a type of CAR-T cell therapy. This therapy targets a specific protein found on certain blood cells and cancer cells. The study will not involve any new treatments but will focus on monitoring participants for any long-term side effects. Participants will be followed for up to 15 years after their last dose of cilta-cel, with check-ups at least once a year. The study will include safety evaluations such as reviewing any side effects, lab test results, and physical exams, including neurological exams.

Description

Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy that targets a protein called BCMA, found on certain blood cells and cancer cells. This study will not provide any new treatment but will monitor participants who have previously received cilta-cel to see if there are any long-term side effects. The study will last up to 15 years after the last dose of cilta-cel, with participants being checked at least once a year. Safety checks will include looking at any side effects, lab test results, and physical exams, including checks on the nervous system.

Eligibility Criteria